SPIT&GO - it gives you freedom, page-2

First 2 Last

Share
Profile

Follow
markess01

295 Posts.

182

22/12/20

11:51

Post #: 49752146
Share

Originally posted by curiouswon: ↑

Across much of the world COVID-19 in original and variant forms is now again requiring increasingly widespread lockdowns to prevent further exponential spreading which can occur from infected but pre-symptomatic persons.
Universal post-movement quarantine coupled with post-symptomatic testing and isolation and treatment (of symptoms) has proved useful and can remain so but is immensely disruptive of society and economy, and is not sustainable as the partial solution.
Vaccines seem to be (in the minds of people and governments) the "Holy Grail", but there is much more evidence needed before safety and widespread efficacy can be demonstrated, and the potential benefits of an effective universal vaccination program achieved. (Another issue here is how quickly the COVID-19 virus will transform (annually?) and how well vaccination will deal with this - noting that viral influenza vaccination is reformulated each year to deal with expected emergent variants of influenza and that it has reported 40-60% success rate).
What society, health and the economy needs is a reliable, low-cost, easily-deployed, rapid test that can detect COVID-19 at pre-symptomatic levels (ie high sensitivity).
A saliva-based test would be ideal.
ADO shareholders will know that ADO seems to be near to this.
But it will need a name!
ADO now names its products professionally - eg AnteoBind - excellent naming.
But for the COVID-19 saliva-based rapid test, ADO may like to reconsider its previous more-populist naming theme whereby the AnteoBind-type products were named Mix&Go - popular non-scientific appeal.

So for the new universal Anteo saliva-based rapid test for COVID-19, I am proposing it be named: Spit&Go.How appealing will that be to the masses! One spit and you are free to go!

Expand

I would prefer Swipe&Go. To me it sounds more marketable

ADO Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

HVN

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

CXU

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

88E

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

PAR

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

There are more pages in this discussion • 8 more messages in this thread...

First 2 Last

Add ADO (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.000(0.00%)		Mkt cap ! $54.77M

Open	High	Low	Value	Volume
2.2¢	2.3¢	2.2¢	$9.979K	449.0K

Buyers (Bids)

No.	Vol.	Price($)
1	354566	2.2¢

Sellers (Offers)

Price($)	Vol.	No.
2.3¢	454657	7

View Market Depth

No.	Vol.	Price($)
1	354772	0.022
11	2009127	0.021
10	1055501	0.020
8	1099486	0.019
6	2172779	0.018

Price($)	Vol.	No.
0.023	378871	6
0.024	213729	5
0.025	1053470	11
0.026	291415	3
0.027	250000	1

Last trade - 12.16pm 18/09/2024 (20 minute delay)

ADO (ASX) Chart

SPIT&GO - it gives you freedom, page-2

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

SPIT&GO - it gives you freedom, page-2

Top Stories

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News